Effect of bevacizumab plus XELOX (CapeOX) chemotherapy on liver natural killer cell activity in colorectal cancer with resectable liver metastasis.

F, Hirata; K, Ishiyama; Y, Tanaka; T, Kobayashi; M, Hashimoto; Y, Saeki; N, Ishida; K, Taguchi; J, Tanaka; K, Arihiro

doi:10.1002/ags3.12195

Effect of bevacizumab plus XELOX (CapeOX) chemotherapy on liver natural killer cell activity in colorectal cancer with resectable liver metastasis.

NobleIDNI5P97W82R94S75

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/CE2ABF97.svg?ark=w1%2F20260526%2FCE2ABF97&value=id)](https://nobleid.org/work/w1/20260526/CE2ABF97)

ARK Inflections

Metadata (JSON)Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work

Effect of bevacizumab plus XELOX (CapeOX) chemotherapy on liver natural killer cell activity in colorectal cancer with resectable liver metastasis.

NobleIDNI5P97W82R94S75

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/CE2ABF97.svg?ark=w1%2F20260526%2FCE2ABF97&value=id)](https://nobleid.org/work/w1/20260526/CE2ABF97)

ARK Inflections

Metadata (JSON)Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work